Early Postpartum Hemorrhage (EPH) is one of the leading causes of postpartum mortality. It is defined as blood loss of at least 500 mL after vaginal or 1000 mL following cesarean delivery within 24 hours postpartum. The following paper includes literature review aimed to estimate the incidence and predictors of early postpartum hemorrhage (EPH). Available prevention and treatment methods were also assessed. The inclusion criteria for the study were met by 52 studies. The exact frequency of EPH in different populations varies from 1.2% to 12.5%. Maternal, pregnancy-associated, laborcorrelated and sociodemographic risk factors seem to be important predictors of EPH. In these cases appropriate prophylaxis should be considered. However, EPH may occur without previous risk factors. The main reason for EPH is uterine atony which contributes to up to 80% of cases of postpartum hemorrhage (PPH). Other common reasons for PPH include genital tract injuries, placenta accreta or coagulopathies. Interestingly, the majority of uterotonics seem to have a similar effect. However, carbetocin seems to be the most effective in certain situations. Appropriate diagnosis of EPH is the most important issue. The treatment should be causative. The first-line treatment should include uterotonics. Surgical interventions, if required, should be performed without delay, although preoperative uterine tamponade should be considered due to its high effectiveness. Medical staff training in medical simulation centers is an important factor that improves the outcomes of EPH treatment. It provides adaptation to hospital protocols, team work improvement, self-confidence building, more accurate blood loss evaluation and reduced perception of stress. The implementation of systematic trainings provides better outcomes in the future.
Keywords: delivery; medical simulation; perinatology; postpartum hemorrhage.
Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage.J Obstet Gynaecol Can. 2009 Oct;31(10):980-993. doi: 10.1016/S1701-2163(16)34329-8. J Obstet Gynaecol Can. 2009. PMID: 19941729 Review.
Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis.Am J Obstet Gynecol. 2020 Apr;222(4):293.e1-293.e52. doi: 10.1016/j.ajog.2019.11.1287. Epub 2020 Jan 6. Am J Obstet Gynecol. 2020. PMID: 31917139
Carbetocin for preventing postpartum haemorrhage.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD005457. doi: 10.1002/14651858.CD005457.pub4. Cochrane Database Syst Rev. 2012. PMID: 22513931 Review.
Carbetocin for preventing postpartum haemorrhage.Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005457. doi: 10.1002/14651858.CD005457.pub3. Cochrane Database Syst Rev. 2012. PMID: 22336812 Updated. Review.
Current research on carbetocin and implications for prevention of postpartum haemorrhage.Reprod Health. 2018 Jun 22;15(Suppl 1):94. doi: 10.1186/s12978-018-0529-0. Reprod Health. 2018. PMID: 29945640 Free PMC article. Review.